ClearPoint Neuro (NASDAQ:CLPT) surged 50% on Wednesday after partner company UniQure announced a significant regulatory milestone for its Huntington’s disease treatment candidate, AMT-130.
Investors responded positively to the update, which could accelerate development of a therapy that relies on ClearPoint’s technology platform for delivery.
UniQure Receives Positive FDA Feedback
UniQure (NASDAQ:QURE) disclosed that the U.S. Food and Drug Administration has agreed that three-year data from its Phase I/II clinical study may serve as the primary basis for a Biologics License Application seeking accelerated approval of AMT-130.
The feedback was provided during a recent Type B meeting with the agency.
The company plans to submit its BLA during the third quarter of 2026, marking a potentially important step toward commercialization.
ClearPoint Technology Used in AMT-130 Administration
AMT-130 is delivered using ClearPoint Neuro’s navigation platform together with its SmartFlow cannula system.
As a result, progress in the development of the Huntington’s disease therapy is viewed as a positive indicator for the broader adoption and validation of ClearPoint’s neurosurgical technologies.
The market reaction reflected growing expectations that successful advancement of AMT-130 could increase visibility for the company’s platform within the gene therapy and neurological disease sectors.
Confirmatory Study Discussions Continue
According to UniQure, the FDA is working with the company to finalize the design of a confirmatory study that would support the accelerated approval pathway.
Among the issues being evaluated is the possibility of using a concurrent control group receiving standard-of-care treatment rather than a sham procedure.
The agency indicated that it intends to work as quickly as possible with UniQure to align on the study design before the BLA submission.
AMT-130 Holds Multiple Regulatory Designations
The treatment candidate has already received several important FDA designations designed to support its development.
These include Regenerative Medicine Advanced Therapy (RMAT) designation, Breakthrough Therapy designation and Fast Track designation.
Notably, AMT-130 became the first Huntington’s disease programme to receive RMAT status from the FDA.
Next Steps Ahead of Filing
UniQure expects to receive the official minutes from the Type B meeting within the next 30 days.
The company reiterated its commitment to moving forward with the confirmatory study without delay and intends to continue working with regulators to finalize the required details ahead of the planned BLA submission.
The regulatory progress boosted sentiment toward ClearPoint Neuro, whose delivery technology remains an important component of the AMT-130 development programme.